[1] |
Wang Z,Han W,Xue F,et al. Nationwide gastric cancer prevention in China,2021-2035: a decision analysis on effect,affordability and cost-effectiveness optimisation[J]. Gut,2022,71(12):2391-2400.
|
[2] |
李磊,费建东,宋利琴,等.新辅助化疗结合腹腔镜胃癌根治术治疗进展期胃癌的生存质量及生存率分析[J/CD].中华普外科手术学杂志(电子版),2020,14(01):66-69.
|
[3] |
国家卫生健康委员会.胃癌诊疗规范(2018年版)[J].中华消化病与影像杂志(电子版),2019,9(03):118-144.
|
[4] |
Fong C,Johnston E,Starling N. Neoadjuvant and Adjuvant Therapy Approaches to Gastric Cancer[J]. Curr Treat Options Oncol,2022,23(9):1247-1268.
|
[5] |
Chen L,Kong X,Wang Z,et al. Pre-treatment systemic immune-inflammation index is a useful prognostic indicator in patients with breast cancer undergoing neoadjuvant chemotherapy[J]. J Cell Mol Med,2020,24(5):2993-3021.
|
[6] |
Feng L,Xu R,Lin L,et al. Effect of the systemic immune-inflammation index on postoperative complications and the long-term prognosis of patients with colorectal cancer: a retrospective cohort study[J]. J Gastrointest Oncol,2022,13(5):2333-2339.
|
[7] |
Japanese Gastric Cancer Association. Japanese gastric cancer treatment guidelines 2014(ver. 4)[J]. Gastric Cancer,2017,20(1):1-19.
|
[8] |
Japanese Gastric Cancer Association. Japanese gastric cancer treatment guidelines 2018(5th edition)[J]. Gastric Cancer,2021,24(1):1-21.
|
[9] |
Japanese Gastric Cancer Association. Japanese gastric cancer treatment guidelines 2018(5th edition)[J]. Gastric Cancer,2021,24(1):1-21.
|
[10] |
Xie H,Ruan G,Ge Y,et al. Inflammatory burden as a prognostic biomarker for cancer[J]. Clin Nutr,2022,41(6):1236-1243.
|
[11] |
Namikawa T,Yokota K,Yamaguchi S,et al. Evaluation of Systemic Inflammatory Response and Nutritional Biomarkers as Predictive Factors in Patients with Recurrent Gastric Cancer[J]. Oncology,2020,98(7):452-459.
|
[12] |
Zhao DB,Zhang XJ. Thinking of the application of membrane anatomy in gastric cancer surgery after neoadjuvant therapy[J]. Zhonghua Wei Chang Wai Ke Za Zhi,2020,23(7):657-660.
|
[13] |
Capovilla G,Froiio C,Lang H,et al. Complete response after neoadjuvant therapy for gastric cancer: implications for surgery[J]. Chirurg, 2022,93(2):138-143.
|
[14] |
Seika P,Biebl M,Raakow J,et al. The Association between Neoadjuvant Radio-Chemotherapy and Prolonged Healing of Anastomotic Leakage after Esophageal Resection Treated with EndoVAC Therapy[J]. J Clin Med,2022,11(16):4773.
|
[15] |
Nakazawa N,Sohda M,Tateno K,et al. Albumin-derived Neutrophil-to-Lymphocyte Ratio Score as a Marker of Nivolumab Treatment Sensitivity in Gastric Cancer: A Multicenter Study[J]. In Vivo, 2023,37(2):818-824.
|
[16] |
何可,臧洲.T4期胃癌患者行腹腔镜根治术后远期预后的影响因素研究[J/CD].中华普外科手术学杂志(电子版),2021,15(04):404-406.
|
[17] |
Tokumaru S,Koizumi T,Sekino Y,et al. Lymphocyte-to-Monocyte Ratio Is a Predictive Biomarker of Response to Treatment with Nivolumab for Gastric Cancer[J]. Oncology,2021,99(10):632-640.
|
[18] |
Nøst TH,Alcala K,Urbarova I,et al. Systemic inflammation markers and cancer incidence in the UK Biobank[J]. Eur J Epidemiol,2021,36(8):841-848.
|